Strategy+ is advising one of the world’s premier biopharmaceutical companies Pfizer (NYSE: PFE) on the acquisition of Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC). The definitive merger agreement was announced May 16, 2016. Pfizer has agreed to acquire Anacor for a total transaction value of $5.2 Billion in cash.
Note to Editors: This press release may contain forward-looking statements regarding Strategy+’s intentions and interests. These statements are based on current expectations and assumptions that are subject to risks and uncertainties. Actual results may differ materially from those expressed or implied in these statements. The firm does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
